Answers are grounded in this paper and cite their sources.
In the Rh blood system, D is recognized as a highly immunogenic blood protein. It is important in RBC transfusion and/or pregnancy because D alloimmunization carries the risk of producing allogenic anti-D, which can lead to hemolytic transfusion reactions and hemolytic diseases of the fetus and newborn. Researchers try to found more RHD variants by using molecular technologies in combination with serological testings. Here, we report a Chinese female carrying a novel variation at the splice acceptor site of intron 3 in RHD locus (c.487-2A>G), which serologically typed as RhD negative. D antigen status was examined with two different monoclonal IgM (clone: MS-26, D175-2) anti-D antibodies (Abs) (Sanquin, Amsterdam, Netherlands, & Dominion Biologicals limited, Nova Scotia, Canada) in tube techniques. For the negative result, the indirect antiglobulin test (IAT) with two different monoclonal IgG anti-D Abs (clone: TH-28, D4151E4) was performed manually using Ortho microcolumn gel card. Adsorption-elution test was performed with commercial human polyclonal antibody (LiBo Biotech Co., Ltd, Jiangsu, China).1 RhCE phenotyping was assayed with standard hemagglutination tube methods (Shanghai Hemo-Pharmaceutical & Biological Inc., Shanghai, China). Genomic DNA was extracted from peripheral white blood cells using a blood DNA kit (DNA Isolation Kit, Life Technologies, California, USA). RHD zygosity testing was determined by PCR with restriction fragment length polymorphism (PCR-RFLP).2 The polymorphisms of RHD exons and flanking intron regions were assessed by polymerase chain reaction (PCR) and sequencing methods as described previously.3 The sample was from a 21-year-old Han Chinese female visiting the otolaryngology department, with no known history of transfusion or pregnancy. By serology testing of RhD phenotype, a negative result was obtained. The RBCs showed no agglutination with two different monoclonal IgM Abs (MS-26, D175-2) by saline tube tests and two different monoclonal IgG Abs (TH-28, D4151E4) by IAT. Further the adsorption-elution test with human polyclonal anti-D confirmed RhD negative phenotype. The RhCE phenotype was determined to be C + E-c + e+. RHD zygosity testing confirmed that the donor had only one RHD allele, that was hemizygous (RHD/RHD deletion). DNA sequencing analysis revealed a new c.487-2A>G variation in the flanking splicing site in intron 3 near exon 4 of RHD gene, designated as IVS3-2A>G. No changes were found in RHD exons 1–10. The serology and genotyping results were summarized in Table 1. The sequence was deposited as GenBank Accession Number PP489225. Disruption of constitutive splice sites is a common mechanism causing gene expression alteration. Single-nucleotide variation (SNV) in RHD gene can disrupt existing, create novel, or activate cryptic splice sites, thereby altering quantitatively and/or qualitatively the expression of the D antigen. The typical example is the Asian DEL allele, RHD*DEL1.4 Experimental evidence showed that missense SNVs located in constitutive splice sites and their vicinity damage quantitatively D antigen expression by, at least, two different mechanisms (splicing alteration and protein destabilization) that may act independently.5 In conclusion, this study reports a molecular genetic study of a Chinese patient and identified a new variant (c.487-2A>G) in the RHD gene. The new variation is located in the flanking splicing site other than exons, which may affect protein expression by interfering with mRNA maturation or/and protein structure, leading to a D-phenotype. Supported by grant from Shandong Blood Transfusion Association Research and Education Commission Research Program Project, China (2021-sdsx01). All of the authors have confirmed that there are no conflicts of interest.
No takes yet. Share an insight, caveat, or question.
Zhu et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: